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Introduction
Ghrelin is a peptide hormone regulating food intake
and stimulating releasement of growth hormone (GH).
It was discovered in 1999 by Kojima et al [1]. The
purification of ghrelin was performed by screening
several tissues and high amount of this hormone was
found in stomach extracts [2]. The discovery of ghre-
lin was rooted in the search for an endogenous ligand
for the growth hormone secretagogue receptor (GHS –
R) [1]. The word ghrelin originally comes from word
ghre which means in Proto-Indo-European language
"grow" [3]. 
The main organ that produces ghrelin is stomach
and immunohistochemical analysis has indicated that
it is produced in a distinct endocrine call known as
X/A – like cells distributed in the mucosal layer of
stomach [4,5]. These cells contain round, compact,
electron – dense granules. The most abundant source
of ghrelin synthesis is gastric fundus  which produces
ten times more of the hormone than the duodenum
[4,6,7]. The cells secreting ghrelin are also present in
the small and large bowel [4]. Most of X/A – like cells
are "closed", what means that they do not directly con-
tact the gastric lumen [4,8]. Minor amounts of ghrelin
are produced in the lungs, pancreatic islets, gonads,
adrenal cortex, placenta and brain [9]. In the central
nervous system ghrelin neuronal cells were identified
in the hypothalamic arcuate nucleus what is the region
of appetite control [3]. The concentration of ghrelin in
human blood samples is 100 – 120 fmol/ml [10]. 
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Ghrelin is a 28 amino acid peptide with an essential
n – octanoyl modified by an acyl acid [11]. The human
ghrelin gene is localized on chromosome 3 (3p 25-26),
contains 4 exons and 3 introns [11].      
The main regulator of plasma ghrelin level is food
intake [11,12]. Plasma ghrelin level is increased during
starvation and decreased after meals [11]. Oral or
intravenous administration of glucose decreases plas-
ma ghrelin concentration [13]. Plasma ghrelin level is
low in obese people and high in lean people [11]. Peo-
ple suffering from anorexia nervosa have highly
increased levels of plasma ghrelin [14]. 
Ghrelin is a very important factor in energy home-
ostasis, a strong orexigenic and adipogenic molecule
[11]. Administration of this hormone stimulates
appetite, food intake and promotes weight gain [15].
Circulating ghrelin levels decrease with feeding and
increase before meals [15]. This protein stimulates
appetite through the hypothalamic arcuate nucleus
[14]. The arcuate nucleus is also the target site of lep-
tin, an appetite – suppressing hormone from adipose
tissues [15].
Circulating ghrelin activate neurons expressing
neuropeptide Y (NPY) and agouti – related peptide
(AGRP) in the arcuate nucleus [11,14]. Both NPY and
AGRP stimulate food intake [14]. Chronic administra-
tion of ghrelin increases body weight [15].  
Obesity actually is a major public health problem
and is recognized when body mass index (BMI) is
greater than 30. Prevalence of obesity in the USA is
estimated at 31% [16]. More than 15% of the popula-
tion in European countries such as England, Germany
and Poland are obese [17]. Obesity is strongly associ-
ated with comorbidities such as diabetes, hyperten-
sion, coronary artery disease and sleep apnea. Bariatric
surgery is recommended for patients with BMI≥40 or
BMI≥35 with associated comorbidities and it efficient-
ly induces substantial weight loss and improves obesi-
ty – related diseases [18]. The most popular bariatric
procedure in the USA is Roux – Y Gastric Bypass
(RYGB) but in Europe the most often Laparoscopic
Adjustable Gastric Banding is performed [19,20]. 
The aim of our study was evaluation of the activity
of gastric X/A-like cells in obese patients before and
after LAGB and RYGB procedures.
Material and methods
Patients and surgical procedures. The study was performed among
morbidly obese patients who underwent RYGB or LAGB in the 1st
Department of General and Endocrinological Surgery at the Medi-
cal University of Bia³ystok between January and December of
2007. The indications for surgery included BMI≥40 or BMI≥35
with associated comorbidities. Patients with psychiatric disorders
or older than 65 years old were excluded. 
Eighteen patients took part in the study. There were 14 females
and 4 males in mean age 45.4±11.46 years old with mean body
weight 140.6±23.5 kg and mean BMI 50.5±7.57. LAGB was 
performed in 7 patients (7 females) at the mean age 34±9.67 with
mean body weight 127.67±4.9 kg and mean BMI 44.3±3.7. RYGB
was performed in 11 patients (7 females and 4 males) at the mean
age 50.9±7.8 with mean body weight 147.1±26.6 and mean BMI
54.5±6.72. The control group of patients consisted of 7 patients
admitted because of chronic cholecystitis. There were 6 females
and 1 male in mean age 43±18 years old with mean body weight
64.7±10.88 kg and mean BMI 24.9±4.41.    
RYGB was performed in open method and it consists of 3 basic
steps. Each operation started with the creation of a gastric pouch
followed by gastrojejunostomy. Jejunojejunostomy about 100 cm
down the Roux limb was made at the end. Gastrojejunostomy was
performed with circular stapler and circular specimen of stomach
was collected for immunocytochemical research. 
LAGB is purely restrictive bariatric method. The procedure
needs special silicone band containing balloon connected with the
drain to the port. LAGB consists of dissection of the proximal
stomach and band placement. The port gives possibility for band
diameter regulation.   
Measurement of ghrelin plasma concentration. Peripheral blood
was taken from each morbidly obese patient before and first day,
seventh day, 1 month and 3 months after surgery. Blood was col-
lected into polypropylene tubes without anticoagulant. Within 2
hours of collection, the blood samples were centrifuged (4000 × for
20 min). The serum was removed using sterile technique and
immediately frozen at -30°C until a consequent analysis. Ghrelin
level was determined by the double – antibody radioimmunoassay
technique. The protocol for radioimmunoassay kit is accessible on
the web site: www.phoenixpeptide.com.
The immunocytochemical study. The circular specimens of stom-
ach were taken from circular stapler after gastrojejunostomy dur-
ing RYGB. Then specimens were fixed in Bouin's fluid for one day
at 4°C. After thorough washing in 0.1 M phosphate buffer
(pH=7.4) at 4°C, the tissues were routinely embedded in paraffin,
and 5 – µm – thick sections were cut. For blocking of the endoge-
nous peroxidase activity Peroxidase Blocking Reagent (Dako
Poland) were used over 10 minutes. In these studies a specific anti-
body against ghrelin (Phoenix) were used. After washing with dis-
tilled water and 0.05 M TRIS – HCl pH=7.4, three times for 5 min-
utes, the sections were incubated with the antibody for 1 hour at
room temperature. Then, sections were washed three times in TRIS
buffer. Subsequently, the EnVision method was applied, according
to the protocol for identification of the immunocytochemical reac-
tion [21]. The sections were counterstained with Mayer's haema-
toxylin. In the negative control, the specific antibodies were omit-
ted in the staining procedure. Positive controls were done for spe-
cific tissue recommended by the producer. The histological prepa-
rations were subjected to analysis, using Olympus B ×50 micro-
scope.
Image analysis. To quantify immunoreactivity of the examined
marker, computerized image analysis were performed. Images
were captured via video link to an Olympus BX50 microscope at
20 objective magnification, so the tissue fully occupied each field,
and was scanned by the computer. Pictures were adjusted for opti-
mal contrast, fixed at the same brightness levels, and saved in a
buffering system. Staining was analyzed using Olympus Cell D
image analysis computer system as described in details by Postek
et al. [22]. The average optical density was analyzed for cells
expressing ghrelin in both, experimental and control specimens.
The average optical density is the method measured values range
from 0 to 255 where 0 means black and 255 white color. 
Ethical issues. The study protocol was approved by the Ethics
Committee Medical University of Bia³ystok and written informed
consent was obtained from each participant.
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Statistical analysis. All values were given as mean ±SD. The
Mann-Whitney test was used for testing the differences between
both groups in the intensity of immunocytochemical reactions. The
Student-T test was used for the evaluation of the differences
between groups in ghrelin plasma concentrations and in decrease
of weight. The value p<0.05 was considered to be significant.       
Results
The mean BMI one month after RYGB was 46.89, 3
months – 42.91, 6 months – 40.52 and 12 months
34.67 (Fig. 1). The mean excess weight loss (EWL)
after RYGB was 21.26% at the end of first month,
38.01% -3th month, 47.04% – 6th month and 66.36% –
12 month (Fig. 3). The mean BMI 1 month after
LAGB was 40.36, 3 months – 35.95, 6 months – 30.84
and 12 months – 26.85 (Fig. 2). The mean EWL after
LAGB was 22.28% at the end of first month, 39.48%
– 3th month, 44.84% – 6th month, and 55.14% – 12
month (Fig. 3).
The mean ghrelin concentration before surgery in
both LAGB and RYGB treated groups was similar and
correspondingly 94.2±52.9 and 81.2±21.9 pg/ml. In
both groups substantial decrease of ghrelin plasma
concentration was observed at first day after surgery
(Fig 4,5). The mean ghrelin concentration first day,
seventh day, 1 month after LAGB was corresponding-
ly 42.42±12.3, 87.17±24.4, 79.55±21.8 and after
RYGB – 37.4±16.4, 66.6±31.8, 92.8±38.9. The signif-
icant increase of ghrelin plasma concentration (mean
values 140.6±49.2 pg/ml) 3 months after LAGB as
compared to the mean value (80.2±27.6 pg/ml) 3
months after RYGB was observed. The mean ghrelin
concentration in the control group was 141.6±21.5
pg/ml. The means results of ghrelin plasma concentra-
tions after LAGB and RYGB are presented in Table 1.
Results of histological study
Ghrelin immunoreactive (Ghr-IR) cells were distrib-
uted predominantly as single cells, locally in varying
number in the deep zone of the gastric mucosa (Fig. 6).
Ghr-IR cells were most abundant in lower parts of gas-
tric proper glands, while in the neck zone of the glands
they were observed sporadically, both in the control
and in the experimental group. These cells were usual-
ly round or oval, sometimes spindle-shaped, seldom
irregular with short processes. Their nuclei were usu-
ally large, round structures that occupy the central por-
tions of cells. While in the X/A like cells of morbidly
obese GH-immunoreactivity appeared as a very strong
reaction (Fig. 7), the GH-immunoreactivity of X/A
like cells not-obese patients was weaker (Fig. 8). The
average optical density of immunocytochemical gas-
tric mucosa reaction for ghrelin, evaluated by Olym-
pus Soft program, was significantly decreased in mor-
bidly obese in comparison to the control not-obese
patients (Fig. 9).
Discussion
The main finding of the present study is the hypoac-
tivity of gastric X/A-like cells in obese patients in
comparison to the control group, confirmed by
immunohistochemical study and ghrelin plasma con-
centration. We observed very strong immunohisto-
chemical reactions of gastric X/A-like cells, accompa-
nied by lower ghrelin plasma concentration in compar-
ison to the control group. The ghrelin plasma level was
significantly decrease 1 day after LAGB and RYGB
procedures, but in the next points of our observations
(7 days, 1 and 3 months after surgery) the plasma con-
centration of investigated hormone started to increase
to the similar level as we noted before surgery. We
haven't noted any statistical differences in ghrelin
plasma level between two investigated groups after 1
day, 7 days and 1 month, but significantly lower ghre-
lin plasma concentration 3 months after RYGB in
comparison to the LAGB procedure. 
The regulation of ghrelin synthesis and secretion in
physiological and pathological condition is still
unknown and controversial. Total fasting ghrelin lev-
els are decreased in human obesity, which might rep-
resent a compensatory response to a sustained positive
energy balance [15]. Among obese otherwise healthy
adults plasma ghrelin concentrations are lower in the
most of insulin resistant subjects relative to equally
obese individuals with relatively higher insulin sensi-
tivity [23]. The only exception to the negative associ-
ation between body mass index and ghrelin secretion is
the Prader-Willi syndrome where obesity is surprising-
ly associated with ghrelin hypersecretion [24]. The
mechanism of down-regulated ghrelin secretion in
obese patients is still unknown [24]. In animals, ghre-
lin is secreted in a pulsatile manner without strict cor-
relation with GH levels but in association with food
intake episodes [13,15]. In humans, ghrelin secretion
undergoes marked variations throughout the day, with
peaks preceding food intake, suggesting that the latter
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Table 1. The means ghrelin plasma concentrations (pg/ml). Values are means ±SD, *p<0.05, **p<0.001 vs  before surgery (student's test). 
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Fig. 6. Light micrograph of gastric mucosa of a control patient.
Positive immunohistochemical reaction for ghrelin is observed in
X/A like cells in the deep zone of the gastric mucosa (original
magnification ×100).
Fig. 1. The decrease of BMI after RYGB. Values are means ±SD,
*p<0.05, **p<0.001  vs BMI before surgery (student's test).
Fig. 2. The decrease of BMI after LAGB. Values are means ±SD,
*p<0.05, **p<0.001, ***p<0.0001 vs  BMI before surgery (Student's
test).
Fig. 3. EWL (%) during 12 months follow up after RYGB and
LAGB. 
Fig. 4. The ghrelin plasma concentration before and after RYGB.
Values are means ±SD, *p<0.05 vs 1 day after surgery (student's
test).
Fig. 5. The ghrelin plasma concentration before and after LAGB.
Values are means ±SD, *p<0.05  vs 1 day after surgery (student's
test).
is triggered by ghrelin discharge [24]. Circulating
ghrelin levels are negatively associated with body
mass index; ghrelin secretion is increased in anorexia
and cachexia, reduced in obesity and normalized by
recovery of ideal body weight [24].
In our present study  hypoactivity of gastric ghre-
lin-positive cells, confirmed by strong immunoreactiv-
ity and lower ghrelin plasma concentration in compar-
ison to the control group, may be a consequence of
increasing secretion of insulin as a result of positive
energy balance in obese. The correlation of body mass
index (BMI) with risk for type 2 diabetes mellitus  is
positive and the association between obesity and
insulin resistance is largely due to changes in the func-
tion of adipose tissue, specifically, increased release of
free fatty acids and abnormalities in adipokine secre-
tion [25]. The properties of visceral adipose tissue may
provide cause these dysfunctions to become magnified
[25]. Saad et al [26] in 2002 reported that hyperinsu-
linemia reduced plasma ghrelin concentration. Ghrelin
secretion is decreased by either intravenous or oral
glucose load as well as during euglycaemic-hyperin-
sulinaemic clamp and even after insulin-induced hypo-
glycaemia [26]. The inhibitory influence of overexpo-
sure to insulin on ghrelin secretion is consistent with
the strong negative association between ghrelin and
insulin levels that had been predicted by the negative
correlation between ghrelin levels and body mass
index, however, it is still unclear whether insulin and
glucose per se play a direct inhibitory role in ghrelin
secretion [26]. Jyh-Ming Liou et al [27] demonstrated
that in nondiabetic obese patients the insulin and glu-
cose  levels  were higher in comparison to healthy sub-
jects.
Another hypothesis trying to explain perturbation
of ghrelin secretion after bariatric surgery is denerva-
tion of autonomic nervous system regulating the activ-
ity of ghrelin-producing tissue in the foregut. It was
demonstrate that vagotomy in rats eliminates the
increase of ghrelin that normally accompanies weight
loss, as is often observed after RYGB [28]. Severing of
vagal input to the foregut is accomplished variably by
different surgeons performing RYGB, so this hypothe-
sis could explain some of the heterogeneity in data per-
taining to the effect of this operation on ghrelin levels
[29]. A neural mechanism might also explain the very
rapid decline in ghrelin levels observed within 
24 hours of the operation [30]. In our present study we
also observed rapid decrease of ghrelin plasma con-
centration one day after RYGB procedure.   
The role of cholinergic nervous system in the regu-
lation of ghrelin secretion was investigated by Maier 
et al [31]. They examined the effects of the cholinergic
antagonist atropine on ghrelin, peptide YY (PYY), glu-
cose, and insulin under basal conditions and after meal
ingestion in lean and obese subjects [31]. The study
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Fig. 9. Average optical density of immunohistochemical staining
for ghrelin in X/A-like cells. Values are means ±SD, *p<0.05 vs
control (Mann-Whitney test).Fig. 7. Light micrograph of gastric mucosa of obese patient. Posi-
tive immunohistochemical reaction for ghrelin is observed in X/A
like cells (original magnification ×400).
Fig. 8. Light micrograph of gastric mucosa of a control patient.
Positive immunohistochemical reaction for ghrelin is observed in
X/A like cells (original magnification ×400). 
showed that, atropine led to a decrease in ghrelin con-
centrations comparable and nonadditive with breakfast
ingestion and a significant decrease in both basal and
meal-induced PYY concentrations in lean individuals
[31]. In obese subjects, atropine did not significantly
change ghrelin or PYY concentrations, whereas it
induced a comparable meal-induced glucose concen-
trations in the two study groups [31]. Only lean sub-
jects experienced sustained feelings of satiety after
breakfast. Maier concluded that impaired cholinergic
regulation of the postprandial drop in ghrelin concen-
trations and rise in PYY concentrations might be part
of the deregulated food intake in obese subjects [31].
LAGB is a purely restrictive bariatric procedure
and most studies showed that ghrelin levels increase
after this operation [32]. LAGB is less invasive
method than RYGB, mainly because it is laparoscopic
procedure and  preserves stomach in its anatomic site.
Ghrelin level increases after LAGB in response to the
energy restriction [32]. In our study we observed sim-
ilar tendency in ghrelin plasma concentration. 
Efficiency of RYGB and LAGB procedures was
estimated by EWL- excess weight loss. In each point
of our observation after surgery we observed signifi-
cant reduction of weight (BMI and EWL), but the
EWL was not significantly higher in patients 1 year
after RYGB in comparison to the LAGB procedure.
According to many authors RYGB results in 65% to
69% EWL at first year [33,34]. We have similar result
in our study. LAGB is restrictive procedure, needs
patient's co-operation in treatment process and causes
about 51% EWL at first year [35,36]. Patient should
avoid sweets and high caloric drinks for better effects
after this operation. We have noticed comparable value
of EWL to other studies one year after LAGB.
The greater weight loss after RYGB compared with
LAGB observed by another authors may be an result
of more effective influence on appetite reduction after
RYGB [37,38]. The greater efficacy of RYGB is most
often hypothesized to result from malabsorption and
dumping syndrome [39]. Impairment of ghrelin secre-
tion might account in part for the loss of hunger after
RYGB [40]. The most of studies show decrease of
ghrelin plasma concentration after RYGB, but some
prospective studies revealed no change in ghrelin lev-
els after RYGB, despite the massive weight loss [40-
43].Those heterogeneity in results probably are
because of subtle differences in surgical technique.
The position of the staple line partitioning the stomach
in RYGB could be a critical determinant of weight
loss. Placing this partition even slightly too far to the
left would include part of the fundus  (the richest
source of ghrelin) in the upper gastric pouch, thus fail-
ing to exclude the fundus from contact with food and
undermining override inhibition [39].
Conclusions
In conclusion, our study indicated hypoactivity of gas-
tric X/A-like cells in obese patients confirmed by
immunohistochemical study and ghrelin plasma con-
centration. Moreover LAGB procedure induced
increase of ghrelin plasma level while RYGB proce-
dure induced decrease of this hormone. The mecha-
nism of ghrelin secretion disturbance after RYGB is
not clear.  
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